evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

469 questions · 483 findings · 63 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 117 · 24.2%GRADE not reported 13 · 2.7%Very low 68 · 14.1%Low 141 · 29.2%Moderate 112 · 23.2%High 32 · 6.6%

Gene therapy vs no gene therapy control

Above‐ankle amputation · peripheral arterial disease

Gene therapy showed no clear difference in amputation (above‐ankle amputation of the index limb) compared with no gene therapy control (moderate certainty).

1 finding from 1 review

Aromatherapy vs placebo

Adverse events (common reactions to aromatherapy include skin rashes, dyspnoea, headache, cardiac arrhythmias, hypotension, hypertension or dizziness) · adults and children having any type of surgical procedure under general anaesthesia, regional anaesthesia or sedation, as hospital…

The review found no eligible studies for this question.

1 finding from 1 review

SUPPORTIVE THERAPY vs FAMILY THERAPY

General functioning: No paid work · patients with schizophrenia

It is very uncertain whether SUPPORTIVE THERAPY changes general functioning: No paid work compared with FAMILY THERAPY (very low certainty).

1 finding from 1 review

Photodynamic therapy with verteporfin vs photodynamic therapy with 5% dextrose

BCVA: loss of 15 or more ETDRS letters · people with neovascular age‐related macular degeneration

Photodynamic therapy with verteporfin leads to lower loss of 3 or more lines (15 or more letters) visual acuity ETDRS chart compared with photodynamic therapy with 5% dextrose (high certainty).

1 finding from 1 review

Photodynamic therapy with verteporfin vs photodynamic therapy with 5% dextrose

Six or more lines visual acuity lost · people with neovascular age‐related macular degeneration

Photodynamic therapy with verteporfin leads to lower loss of 6 or more lines (30 or more letters) visual acuity ETDRS chart compared with photodynamic therapy with 5% dextrose (high certainty).

1 finding from 1 review

Photodynamic therapy with verteporfin vs photodynamic therapy with 5% dextrose

Gain of 3 or more lines of visual acuity · people with neovascular age‐related macular degeneration

Photodynamic therapy with verteporfin leads to higher gain of 3 or more lines (15 or more letters) compared with photodynamic therapy with 5% dextrose (high certainty).

1 finding from 1 review

Photodynamic therapy with verteporfin vs photodynamic therapy with 5% dextrose

Adverse effects: acute severe visual acuity decrease · people with neovascular age‐related macular degeneration

Photodynamic therapy with verteporfin showed no clear difference in adverse effects: acute severe visual acuity decrease compared with photodynamic therapy with 5% dextrose (moderate certainty).

1 finding from 1 review

Photodynamic therapy with verteporfin vs photodynamic therapy with 5% dextrose

Adverse effects: infusion‐related back pain · people with neovascular age‐related macular degeneration

Photodynamic therapy with verteporfin leads to higher adverse effects: infusion‐related back pain compared with photodynamic therapy with 5% dextrose (high certainty).

1 finding from 1 review

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + GLP1‐A
2 findings from 1 review

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + DPP4‐I

It is very uncertain whether metformin‐sulphonylurea (second‐ or third‐generation) combination… changes M + DPP4‐I compared with metformin plus another antidiabetic drug (very low certainty).

3 findings from 1 review